Advertisement
ABBV or GILD or GSK
Which Stock Would AI Choose? AbbVie (ABBV) vs. Gilead Sciences (GILD) vs. GSK (GSK) Stock Comparison
Key Takeaways
- ABBV reported robust Q1 2026 revenue of $15 billion, up 12.4% year-over-year, driven by immunology drugs like Skyrizi and Rinvoq.
- GILD leads year-to-date (YTD) performance at approximately 8.5%, supported by HIV pipeline advancements and an upcoming acquisition.
- GSK delivered Q1 sales growth of 5% to £7.6 billion, led by specialty medicines, though shares dipped amid investor concerns over one-off gains.
- All three offer attractive dividend yields above 2.5%, with low betas (around 0.3) indicating relative stability versus the broader market.
- Valuations vary: GSK trades at the lowest price-to-earnings (P/E) ratio of about 13, while ABBV's is elevated near 101.
- Recent analyst upgrades favor ABBV for durable growth into the mid-2030s.
Introduction
This comparison examines three leading pharmaceutical giants: ABBV (AbbVie), GILD (Gilead Sciences), and GSK (GSK plc). All operate in the large-cap pharma sector, focusing on high-margin therapeutics amid patent transitions and pipeline expansions. Investors seeking dividend income, growth potential, or defensive exposure in healthcare may find value here, especially given recent quarterly earnings beats and sector tailwinds like immunology and antivirals. With market caps exceeding $100 billion each, their relative performance highlights trade-offs in valuation, momentum, and risk in the current environment.
ABBV Overview and Recent Performance
AbbVie, spun off from Abbott Laboratories in 2013, is a biopharmaceutical leader specializing in immunology, oncology, and neuroscience. Its portfolio transitioned from Humira dominance to newer blockbusters like Skyrizi (risankizumab) and Rinvoq (upadacitinib). In recent market activity, ABBV shares have shown resilience, trading around $207 with a market cap near $366 billion. Q1 2026 revenue surged 12.4% to $15 billion, beating estimates, fueled by immunology sales. Analyst upgrades, including from Bank of America and Evercore ISI, reflect optimism on durable growth, though elevated P/E (price-to-earnings) ratio of 101 signals premium valuation. Dividend yield stands at 3.35%, with low beta of 0.31 underscoring stability. Sentiment has improved on pipeline wins like Skyrizi formulary listings.
GILD Overview and Recent Performance
Gilead Sciences focuses on antivirals, particularly HIV treatments like Biktarvy, alongside oncology and inflammation therapies. Recent weeks have seen steady performance, with shares near $132 and market cap at $164 billion. YTD gains of about 8.5% outpace peers, supported by FDA priority review for a new HIV regimen and a $4.5 billion Arcellx acquisition to bolster oncology. Q1 earnings are due soon, with expected EPS of $1.89. P/E ratio of 19.5 and 2.49% dividend yield offer balance, while beta of 0.33 indicates low volatility. Momentum stems from pipeline catalysts, though share price has moderated from 52-week highs amid broader market rotations.
GSK Overview and Recent Performance
GSK plc, a global pharma and vaccines powerhouse, excels in respiratory, HIV, and oncology via products like Shingrix and Dovato. Shares trade around $51 with a $102 billion market cap. Q1 2026 sales rose 5% to £7.6 billion at constant rates, driven by 14% specialty medicines growth, reaffirming full-year guidance. However, shares slid post-earnings on questions over one-off boosts and general medicines misses. Lowest P/E among peers at 13.25, paired with 3.49% yield, appeals to value seekers; beta of 0.30 adds defensiveness. A $950 million acquisition expands the pipeline, countering sentiment dips from leadership shifts.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top performers curated from over 350 AI trading bots that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—such as trend-following, multi-agent pairs, and take-profit/stop-loss (TP/SL) corridors—with impressive stats: annualized returns up to 162%, win rates reaching 88%, profit factors between 1.5 and 3.3, and profit-to-drawdown ratios as high as 17. Many target volatile sectors like semiconductors (e.g., NVDA, AMD), space (ASTS, GSAT), and industrials, adapting to current conditions via real-time signals. Virtual and brokerage agents include risk management for live trading. Traders can explore these high-probability options tailored to today’s market.
Head-to-Head Comparison
ABBV, GILD, and GSK share defensive pharma exposure but diverge in models: AbbVie emphasizes immunology growth post-patent cliffs, Gilead stable HIV revenues with oncology bets, and GSK diversified vaccines/respiratory. Growth drivers contrast—AbbVie’s 12% revenue surge versus GSK’s 5% and Gilead’s projected modest EPS rise. Recent momentum favors Gilead’s YTD edge, but AbbVie shows trend consistency. Risks include pipeline failures and biosimilar competition across all. Valuation sensitivity highest for AbbVie’s premium P/E; GSK offers value trade-off. Market sentiment tilts positive on AbbVie catalysts, balanced by Gilead’s acquisitions and GSK’s yields.
Tickeron AI Verdict
Tickeron’s AI models currently favor ABBV with the highest probability of near-term outperformance, based on revenue momentum, analyst upgrades, and immunology pipeline stability amid recent beats. Gilead follows closely on YTD positioning and catalysts, while GSK lags on post-earnings sentiment despite attractive valuation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s), and GSK’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- GILD’s FA Score: 3 green, 2 red.
- GSK’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while GILD’s TA Score has 4 bullish TA indicator(s), and GSK’s TA Score reflects 4 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- GILD’s TA Score: 4 bullish, 4 bearish.
- GSK’s TA Score: 4 bullish, 6 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +4.39% price change this week, while GILD (@Pharmaceuticals: Major) price change was -1.33% , and GSK (@Pharmaceuticals: Major) price fluctuated +0.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.06%. For the same industry, the average monthly price growth was -2.23%, and the average quarterly price growth was +2.30%.
Reported Earning Dates
ABBV is expected to report earnings on Jul 24, 2026.
GILD is expected to report earnings on Jul 30, 2026.
GSK is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.06% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| ABBV | GILD | GSK | |
| Capitalization | 372B | 161B | 102B |
| EBITDA | 17.6B | 14.5B | 10.1B |
| Gain YTD | -6.411 | 6.172 | 3.850 |
| P/E Ratio | 103.13 | 17.63 | 12.92 |
| Revenue | 61.2B | 29.7B | 32.8B |
| Total Cash | N/A | 7.64B | N/A |
| Total Debt | 67.5B | 22.2B | N/A |
ABBV | GILD | GSK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 20 | 7 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 25 Undervalued | 20 Undervalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 14 | 40 | |
SMR RATING 1..100 | 1 | 22 | 26 | |
PRICE GROWTH RATING 1..100 | 56 | 58 | 58 | |
P/E GROWTH RATING 1..100 | 22 | 66 | 81 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GSK's Valuation (8) in the Pharmaceuticals Major industry is in the same range as GILD (20) in the Biotechnology industry, and is in the same range as ABBV (25) in the Pharmaceuticals Major industry. This means that GSK's stock grew similarly to GILD’s and similarly to ABBV’s over the last 12 months.
GILD's Profit vs Risk Rating (14) in the Biotechnology industry is in the same range as ABBV (14) in the Pharmaceuticals Major industry, and is in the same range as GSK (40) in the Pharmaceuticals Major industry. This means that GILD's stock grew similarly to ABBV’s and similarly to GSK’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as GILD (22) in the Biotechnology industry, and is in the same range as GSK (26) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to GILD’s and similarly to GSK’s over the last 12 months.
ABBV's Price Growth Rating (56) in the Pharmaceuticals Major industry is in the same range as GILD (58) in the Biotechnology industry, and is in the same range as GSK (58) in the Pharmaceuticals Major industry. This means that ABBV's stock grew similarly to GILD’s and similarly to GSK’s over the last 12 months.
ABBV's P/E Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (66) in the Biotechnology industry, and is somewhat better than the same rating for GSK (81) in the Pharmaceuticals Major industry. This means that ABBV's stock grew somewhat faster than GILD’s and somewhat faster than GSK’s over the last 12 months.
| ABBV | GILD | GSK | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 58% | 3 days ago 78% |
| Stochastic ODDS (%) | 3 days ago 39% | 3 days ago 32% | 3 days ago 64% |
| Momentum ODDS (%) | 3 days ago 65% | 3 days ago 44% | 3 days ago 51% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 64% | 3 days ago 53% |
| TrendWeek ODDS (%) | 3 days ago 59% | 3 days ago 44% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 61% | 3 days ago 49% | 3 days ago 49% |
| Advances ODDS (%) | 4 days ago 57% | 6 days ago 61% | 5 days ago 61% |
| Declines ODDS (%) | 10 days ago 48% | 3 days ago 46% | 3 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 63% | 3 days ago 50% | 3 days ago 75% |
| Aroon ODDS (%) | 3 days ago 58% | 3 days ago 46% | 3 days ago 43% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GGM | 28.74 | N/A | N/A |
| GGM Macro Alignment ETF | |||
| MMTM | 313.84 | -1.71 | -0.54% |
| State Street® SPDR® S&P® 1500MomtTiltETF | |||
| FDD | 19.21 | -0.26 | -1.34% |
| First Trust STOXX European Select Dividend Income Fund | |||
| IEFA | 95.21 | -1.70 | -1.75% |
| iShares Core MSCI EAFE ETF | |||
| IDEF | 31.84 | -1.03 | -3.13% |
| iShares Defense Industrials Active ETF | |||
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.18% | ||
| PFE - ABBV | 57% Loosely correlated | -1.63% | ||
| BMY - ABBV | 55% Loosely correlated | +0.41% | ||
| AMGN - ABBV | 48% Loosely correlated | -2.22% | ||
| NVS - ABBV | 47% Loosely correlated | -1.13% | ||
| MRK - ABBV | 46% Loosely correlated | -1.79% | ||
More | ||||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.